Initial results from a first-in-human study of the B7-H4-directed antibody-drug conjugate (ADC) AZD8205 (puxitatug samrotecan) in patients with advanced/metastatic solid tumors

被引：5

作者：

Meric-Bernstam, F. ^{[1
]}

Naito, Y. ^{[2
]}

Gaillard, S. ^{[3
]}

Shimoi, T. ^{[4
]}

Chung, V. ^{[5
]}

Davis, A. A. ^{[6
]}

Proia, T. ^{[7
]}

Ayyoub, A. ^{[8
]}

Kulkarni, M. ^{[8
]}

Upadhyay, S. ^{[9
]}

Miller, N. ^{[9
]}

Luheshi, N. ^{[9
]}

Varga, A. ^{[9
]}

Oh, D-Y. ^{[10
]}

Mileshkin, L. ^{[11
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Invest Canc Therapeut Dept, Houston, TX USA

[2] Natl Canc Ctr Hosp East, Dept Gen Internal Med, Chiba, Japan

[3] Johns Hopkins Univ, Oncol & Gynecol Obstet, Baltimore, MD USA

[4] Natl Canc Ctr, Oncol Dept, Chuo Ku, Tokyo, Japan

[5] City Hope Comprehens Canc Ctr, Dept Med Oncol, Duarte, CA USA

[6] Washington Univ Sch Med St Louis, Div Hematol & Oncol, Dept Med, St Louis, MO USA

[7] AstraZeneca, Waltham, MA USA

[8] AstraZeneca, Oncol, Gaithersburg, MD USA

[9] AstraZeneca, Oncol R&D, Cambridge, England

[10] Seoul Natl Univ, Coll Med, Seoul Natl Univ Hosp, Internal Med Dept,Canc Res Inst, Seoul, South Korea

[11] Peter MacCallum Canc Ctr, Dept Med Oncol, Parkville, Vic, Australia

来源：

关键词：

D O I：

10.1016/j.annonc.2024.08.673

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

606O

引用

页码：S485 / S486

页数：2